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A B S T R A C T
Breakdown of the endothelial barrier is a critical step in the development of organ failure in severe inﬂammatory
conditions such as sepsis. Endothelial cells from diﬀerent tissues show phenotypic variations which are often
neglected in endothelial research. Sphingosine-1-phosphate (S1P) and AMP-dependent kinase (AMPK) have been
shown to protect the endothelium and phosphorylation of AMPK by S1P was shown in several cell types.
However, the role of the S1P-AMPK interrelationship for endothelial barrier stabilization has not been in-
vestigated. To assess the role of the S1P-AMPK signalling axis in this context, we established an in vitro model
allowing real-time monitoring of endothelial barrier function in human microvascular endothelial cells (HMEC-
1) and murine glomerular endothelial cells (GENCs) with the electric cell-substrate impedance sensing (ECIS™)
system. Following the disruption of the cell barrier by co-administration of LPS, TNF-α, IL-1ß, IFN-γ, and IL–6,
we demonstrated self-recovery of the disrupted barrier in HMEC-1, while the barrier remained compromised in
GENCs. Under physiological conditions we observed a rapid phosphorylation of AMPK in HMEC-1 stimulated
with S1P, but not in GENCs. Consistently, S1P enhanced the basal endothelial barrier in HMEC-1 exclusively.
siRNA-mediated knockdown of AMPK in HMEC-1 led to a less pronounced barrier enhancement. Thus we
present evidence for a functional role of AMPK in S1P-mediated barrier stabilization in HMEC-1 and we provide
insight into cell-type speciﬁc diﬀerences of the S1P-AMPK-interrelationship, which might inﬂuence the devel-
opment of interventional strategies targeting endothelial barrier dysfunction.
1. Introduction
Systemic inﬂammation in the critically ill patient is often accom-
panied by an impairment of the microcirculation [1] that contributes to
the development of organ dysfunction [2]. The exposure of the micro-
vascular endothelium to inﬂammatory mediators can result in an acti-
vated pro-coagulant state with microthrombi formation as well as a
severe impairment of the endothelial barrier [3]. This leads to capillary
leakage and interstitial oedema resulting in decreased tissue oxygena-
tion facilitating the onset of organ dysfunction [4]. Thus, the devel-
opment of preventive or therapeutic strategies stabilizing endothelial
barriers may improve the outcome in patients suﬀering from conditions
associated with severe systemic inﬂammation, such as sepsis.
Sphingosine-1-phosphate (S1P) is a bioactive lipid mediator circu-
lating mostly in the blood, inﬂuencing cellular migration, proliferation
and survival via its G protein-coupled receptors S1P1–5 [5]. S1P potently
promotes barrier function in vitro [6–8] and is essential for maintenance
of endothelial barriers in vivo [9,10]. Our group and others have shown
that serum S1P levels are lower in septic patients and correlate nega-
tively with the severity of disease. This indicates a role of S1P in the
pathophysiology of endothelial dysfunction [11–13]. FTY720 – a
clinically approved S1P analogue for treatment of multiple sclerosis –
enhances the endothelial barrier in cultured pulmonary or brain en-
dothelial cells [14–16] and reduces barrier-permeabilizing eﬀects of
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VEGF [17] and TNF–α [15,18]. In a previous study by our group, ad-
ministration of FTY720 improved cardiac dysfunction and was asso-
ciated with elevated S1P serum levels in murine sepsis models [11].
Others have further shown that FTY720 reduces ﬂuid extravasation in a
rat model of sepsis [19] and lung microvascular permeability in LPS-
challenged mice [20]. Additionally, Imeri et al. [15,18] reported a
protective eﬀect of FTY720 and S1P in the human endothelial cell line
EA.hy 926 and in mouse and human microcapillary brain endothelial
cells. This protection was suggested to involve an upregulation of the
adherens junction molecule PECAM-1 (CD31) [15]. Targeting the S1P
pathway might consequently be an interesting therapeutic approach to
stabilize microvascular endothelial barriers. The eﬀects of FTY720 on
the glomerular endothelium in an inﬂammatory state have not yet been
investigated.
The heterotrimeric AMP-dependent protein kinase (AMPK) is widely
expressed in the endothelium [21] and previous in vivo and in vitro
studies have shown that AMPK exerts anti-inﬂammatory and protective
eﬀects on the endothelial barrier under inﬂammatory conditions
[22–24]. Of note, S1P is one of the agonists that can activate AMPK and
targets further downstream in cultured bovine aortic cells [25] as well
as human umbilical vein endothelial cells and baby hamster kidney
cells [26,27] indicating that AMPK could be one of the mediators
promoting the barrier-enhancing eﬀects of S1P. However, the interac-
tion of S1P and AMPK has not yet been investigated in the micro-
vascular endothelium and the functional relevance of their inter-
relationship for the endothelial barrier remains unclear.
Although barrier dysfunction mainly aﬀects the microvasculature,
cells derived from the macrovasculature are often used to study en-
dothelial barrier breakdown. It has previously been shown that en-
dothelial cells have heterogeneous phenotypes regarding their perme-
ability depending on the vascular branch from which they originate.
This is, at least in part, inﬂuenced by diﬀerent patterns of adhesion
molecule and tight junction expression [28]. Tissue of origin also plays
an important role, e.g. glomerular endothelium is highly fenestrated
whereas both brain and dermal microvascular endothelial cells belong
to the continuous endothelium. Still, brain and dermal microvascular
endothelial cells diﬀer regarding their caveolin as well as tight junction
protein expression [28]. However, this fact is often neglected and might
explain why in vitro observations often deviate from in vivo ﬁndings
[29].
In this study we aimed to establish an in vitromodel of inﬂammatory
barrier breakdown in the microcirculation that is applicable to en-
dothelial cell lines of various origins (species and tissue) in the electric
cell-substrate impedance sensing (ECIS™) system. In addition to human
microvascular endothelial cells (HMEC-1), we employed murine glo-
merular endothelial cells (GENCs), as the kidney is very sensitive to
inﬂammation-induced organ failure [30] and the glomerular en-
dothelium plays a key role in the progression of renal dysfunction [31].
S1P can phosphorylate AMPK in cells of the human [26] and bovine
[25] macrovasculature as well as in kidney ﬁbroblasts [27]. However,
data on the S1P-AMPK interrelation in the microvasculature have not
been reported. Therefore, we investigated the time courses of AMPK
phosphorylation by S1P in HMEC-1 and GENCs. Subsequently, we
evaluated the physiological relevance of this phosphorylation by
siRNA-mediated knockdown of AMPK α1/2 in HMEC-1, which was
implemented in the ECIS™ system by a reverse transfection protocol.
Finally, we assessed eﬀects of FTY720 on inﬂammatory barrier break-
down in HMEC-1 and GENCs using the in vitro model established in this
study.
2. Methods
2.1. Cell culture
Cell culture media and supplements were purchased by Gibco unless
stated otherwise. HMEC-1 were obtained from Centers for Disease
Control and Prevention (CDC, Atlanta, reference number E-036-91/0)
and cultured in MCDB131 medium supplemented with 10% fetal bo-
vine serum (FBS), 1% glutamine, 10 ng/ml epidermal growth factor and
1 μg/ml hydrocortisone as well as 1% penicillin/streptomycin. HMEC-1
were passaged at 70–80% conﬂuence and used from passage 4–15.
GENCs isolated from immorto mice were obtained from Michael P.
Madaio [32]. Cells were cultured in a DMEM low glucose, pyruvate
medium with 23% Ham's F12 Nutrient Mix, 1% penicillin/streptomycin
(Millipore) with 10% heat-inactivated FBS. GENCs were passaged at
60–70% conﬂuence and cells from passages 5–9 were used in the ex-
periments.
2.2. Inﬂammatory stimulus
Inﬂammatory conditions were simulated using an inﬂammatory
stimulus (LPS+Cyt) containing the endotoxin lipopolysaccharide
(LPS, 100 ng/ml, see Suppl. Table 1) and the pro-inﬂammatory cyto-
kines TNF-α (100 μg/ml), IL-1ß (10 μg/ml), IFN-γ (10 μg/ml) and IL–6
(10 μg/ml). Stock solutions were prepared in DMEM with 1% bovine
serum albumin (BSA, Sigma Aldrich) and were used at dilutions of
1:100, 1:400 and 1:1000 for GENCs. Stock solutions for HMEC-1 cells
were prepared in MCDB131 with 1% BSA and used at dilutions of
1:100, 1:400 and 1:800.
2.3. Measuring endothelial barrier function
Endothelial barrier function was evaluated using the ECIS™ Zθ
system (Applied Biophysics) [33]. 8W10E ECIS Cultureware™ Arrays
(Applied Biophysics) were coated with a solution containing ﬁbronectin
from human plasma (1mg/ml, Biochrome) and mouse collagen IV
(640 μg/ml, BD Biosciences) in phosphate-buﬀered saline (PBS). Elec-
trodes were stabilized via the ECIS™ software. Measurements were
performed in MFT (multiple frequencies per time) mode. Cells were
seeded at a density of 10,000 cells/well (GENCs) or 20,000 cells/well
(HMEC-1). Partial media changes were performed every 24 h until
plateaus in both resistance (around 1200–1400Ω in GENCs, around
1500–1800Ω in HMEC-1) and conﬂuence (around 5 nF for both cell
lines) were reached. Once plateau was observed (approx. 72 h after
seeding the cells), 200 μl medium were replaced with fresh medium
containing inﬂammatory stimulus in various concentrations. S1P was
added at 1 μM without change of medium. Resistance was monitored at
4000 Hz and capacitance at 64,000 Hz. Each manipulation was per-
formed in duplicates. Time was resampled to 600 s and medium control
was subtracted from the mean value of each measurement for nor-
malization.
2.4. Cell stimulation with S1P
48 h prior to stimulation, cells were seeded in 35mm culture dishes
at a density of 50,000 cells/dish (GENCs) or 100,000 cells/dish (HMEC-
1). Cells were subjected to serum starvation 4 h prior to the experi-
ments. Cells were stimulated with 1 μM S1P (Sigma Aldrich, solubilized
in methanol) or the same amount of vehicle for indicated times at 37 °C.
In each experiment, stimulation with 2mM AICAR (aminoimidazole
carboxamide ribonucleotide, CST, solubilized in water) for 30min
served as a positive control for AMPK phosphorylation. Cells were
washed, lysed on ice with lysis buﬀer (1% IGEPAL® CA-630, 50mM Tris
pH 8.0, 150mM NaCl, 5 mM NaF, 1mM Na3VO4, protease inhibitor
cocktail 1:100) and centrifuged at 4 °C and 900 RCF for 7min. Protein
concentration was determined using Pierce Detergent Compatible
Bradford Assay Kit (Thermo Fisher Scientiﬁc) according to the manu-
facturer's protocol and samples were processed with 4× SDS sample
buﬀer (50mM Tris pH 6.8, 2% SDS, 10% glycerol, 1% β-mercap-
toethanol, 12.5mM EDTA, 0.02% bromophenol blue) for im-
munoblotting.
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2.5. Immunoblotting
20 μg of protein were loaded onto 10% TGX Stain-Free™ FastCast™
gels (Bio-Rad). Protein was transferred onto low ﬂuorescent PVDF
membranes (Bio-Rad) using the Trans-Blot® Turbo RTA Transfer Kit and
Trans-Blot® Turbo™ Transfer system (Bio-Rad). Membranes were
blocked in 5% BSA. AMPK α1/2 (CST, LOT no. 19), AMPK α1/2
pThr172 (CST, LOT no. 15) and β-actin (CST, LOT no. 13) antibodies
were used at concentrations of 1:1000. Anti-rabbit IgG, HRP-linked
secondary antibody (CST, LOT no. 27) and anti-mouse IgG, HRP-linked
secondary antibody (CST, LOT no. 33) were used at a concentration of
1:2000. For signal detection, Clarity™ Western ECL substrate (Bio-Rad)
and the ChemiDoc™ MP Imaging System (Bio-Rad) were used. First, the
phospho-signal was detected, then membranes were stripped 15min at
50 °C (stripping buﬀer: 20% SDS, 6.25mM Tris pH 6.8, 0.8% β-mer-
captoethanol) and reprobed with the AMPK α1/2 antibody. Signals
were analysed and background was subtracted using the Image Lab™
software (Bio-Rad). Phosphorylation levels of AMPK were calculated by
dividing AMPK phospho-Thr172 level by total AMPK α1/2 level (Σ
AMPK α1/2). The ratio was normalized to the ratio of the respective
unstimulated control. For analysis of knockdown eﬃciency, AMPK α1/
2 level was normalized to β-actin and the percentage of remaining
AMPK α1/2 signal was calculated relatively to the respective scrambled
siRNA control band. Additionally, knockdown eﬃciency was calculated
by Stain-Free™ quantiﬁcation (Supplementary material).
2.6. Reverse transfection
The concept of reverse transfection of plasmids was introduced in
2001 by Ziauddin and Sabatini [34] and already successfully applied to
siRNA transfection in the ECIS™ system [35]. For reverse transfection,
cells were directly mixed with the transfection reagent instead of
seeding them prior to the transfection protocol. This allowed per-
forming the transfection process without complete media changes that
are diﬃcult to conduct in the ECIS™ system and avoided the need to
split transfected cells before monitoring them. Control siRNA (scram-
bled siRNA), AMPK α1/2 siRNA as well as siRNA Transfection Reagent
were purchased by Santa Cruz Biotechnology. The manufacturer's
protocol was adapted to the smaller volumes used in ECIS™ arrays
(400 μl instead of 1ml) and optimal siRNA as well as Transfection
Reagent dilution which was assessed in 6-well plates. For reverse
transfection in the ECIS™ system, 1.6 μl siRNA as well as 1.6 μl Trans-
fection Reagent per well were prepared according to the adapted pro-
tocol, incubated 45min at RT, pipetted into the respective wells and
mixed with 1× 105 cells. ECIS™ measurement was started immediately
thereafter. 5 h later, FBS and antibiotics were added to a ﬁnal con-
centration of 10% and 1%, respectively. To remove transfection
medium after 24 h, wash-out was performed by 5 partial changes.
Medium was partially changed again after 48 h. After 72 h, S1P sti-
mulation was performed by adding S1P directly to each well to a ﬁnal
concentration of 1 μM. Time was resampled to 600 s, medium control
was subtracted from each measurement for normalization, and changes
were calculated relative to 10min before S1P stimulation.
2.7. FTY720 co-stimulation
Cells were seeded to the ECIS™ array and cultivated until resistance
and capacitance plateaued as described above (Section 2.3). Subse-
quently, 200 μl medium were replaced with fresh medium containing
either only inﬂammatory stimulus, the stimulus and FTY720
(LPS+Cyt 1:400 for HMEC-1 and 1:1000 for GENCs; FTY720 from
Cayman Chemical solubilized in DMSO and added at 1 μM) or in-
ﬂammatory stimulus and DMSO as vehicle.
2.8. Statistical analysis
Statistical analysis was performed using GraphPad Prism 7.03
software. Data are depicted as mean+ SD for n number of independent
experiments. For ECIS™ curves, normalized mean values and standard
deviation were plotted against time starting from the stimulation.
Statistics were performed as two-way ANOVA with Holm-Sidak post hoc
test. Non-parametrical data was analysed by Mann-Whitney-U test.
Outliers were excluded using ROUT test with Q=5.
3. Results and discussion
3.1. Endothelial response to inﬂammatory conditions diﬀers in HMEC-1
and GENCs
To establish an in vitro model of inﬂammatory barrier breakdown,
conﬂuent layers of two diﬀerent cell lines were challenged with
LPS+Cyt to mimic an inﬂammatory environment rather than studying
isolated eﬀects of one inﬂammatory agent. Changes in resistance were
monitored with the ECIS™ system for a period of 24 h.
HMEC-1 responded to the inﬂammatory stimulus with an initial
increase in resistance that was signiﬁcant only in the lowest con-
centration tested (Fig. 1A). After approximately 2 h, resistance sig-
niﬁcantly decreased compared with the control reaching a minimum
peak at around 6 h. This phase of decreased resistance resembling
barrier dysfunction was shortest in the lowest concentration tested and
most pronounced with LPS+Cyt 1:400. The endothelial barrier func-
tion of HMEC-1 subsequently recovered and reached a plateau that was
signiﬁcantly higher in LPS+Cyt 1:100 than in the respective control.
GENCs initially responded with a slight, non-signiﬁcant increase in
resistance (Fig. 1B). After that, resistance slightly decreased under the
level of the control starting with LPS+Cyt 1:100 approximately 4 h,
LPS+Cyt 1:400 approximately 5 h and last, LPS+Cyt 1:1000 ap-
proximately 7 h after stimulation. Until the end of the experiment, all
curves with LPS+Cyt remained signiﬁcantly lower than the control.
Medium rescue was performed to test whether LPS+Cyt induced
permanent damage to the endothelial layer of GENCs (Fig. 1C). After
medium was changed, resistance rapidly recovered to levels that were
comparable to the untreated control.
Cytoskeletal ﬁlaments are known for their important role in barrier
stabilization [36] and LPS was shown to contribute to the dis-
organization of such ﬁlaments resulting in the formation of intracellular
gaps in diﬀerent endothelial cell lines [37,38]. As the changes in HMEC-
1 barrier function were linked to signiﬁcant changes in the conﬂuence
of the cell layer (Suppl. Fig. 1A), but occurred fast and were completely
reversible, they are most probably caused by such fast reorganization
processes in the cytoskeleton resulting in disturbances of cell-cell-con-
tacts. The initial response of GENCs was comparable with HMEC-1 but
less pronounced. Decrease in resistance and hereby endothelial barrier
breakdown started considerably later and in contrast to HMEC-1, no
recovery was observed in this cell line even after 24 h. Of note, capa-
citance also gradually and signiﬁcantly increased with the decrease in
barrier function (Suppl. Fig. 1B), indicating either cell death or pro-
nounced changes in the cytoskeleton.
In conclusion, the inﬂammatory stimulus induced endothelial bar-
rier dysfunction in HMEC-1 and GENCs, indicated by a signiﬁcant de-
crease of resistance. However, the time course and the capability to
recover from the LPS+Cyt challenge signiﬁcantly diﬀered in the two
cell lines. In GENCs, a proportional change of medium allowed the
endothelial barrier to recover rapidly. This indicates that the model is
suitable to study barrier-recovering interventional strategies.
3.2. AMPK is phosphorylated upon S1P stimulation in HMEC-1 but not
GENCs
Prior to testing interventional strategies in the established barrier
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breakdown model, we aimed to characterize the interrelation of S1P
and AMPK in each cell line under basal conditions. AMPK phosphor-
ylation upon stimulation with S1P has been reported [25–27], but not
yet assessed in cells of the microvasculature. We stimulated HMEC-1
and GENCs with 1 μM S1P for diﬀerent time periods to investigate the
course of AMPK phosphorylation. In HMECs, AMPK α1/2 was rapidly
phosphorylated at Thr172 upon S1P stimulation (Fig. 2A, B).
Considerably higher levels of phosphorylation were observable 1min
and 2min after onset of stimulation compared with unstimulated con-
trol, which thereafter, decreased over time to levels that are compar-
able with unstimulated cells. This phosphorylation pattern was absent
in the vehicle control performed in parallel (Suppl. Fig. 2A). S1P sti-
mulation of conﬂuent HMEC-1 cells led to a signiﬁcant increase in re-
sistance and hereby barrier function 2–5 h after onset of stimulation
Fig. 1. Endothelial response to inﬂammatory conditions diﬀers in HMEC-1 and GENCs. ECIS measurement of endothelial barrier function in (A) HMEC-1 (n=3) and
(B) GENCs (n= 3–4) stimulated with LPS, TNF-α, IL-1ß, IFN-γ, and IL–6 (LPS+Cyt) in the respective concentrations 72 h after cell seeding (t= 0 h). (C) Medium
rescue performed by partial media change (indicated by vertical line) 24 h after stimulation with LPS+Cyt (t= 0 h) in GENCs (n=3). (A–C) Data are expressed as
mean ± SD, n= 3–4 measurements, *p < 0.05 vs. control at each respective time point is indicated by bars (two-way ANOVA with Holm-Sidak post hoc).
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(Fig. 2C). In GENCs, no signiﬁcant changes in AMPK phosphorylation
were detected in the period of observation except for 30min of sti-
mulation (Fig. 2D, E). However, the same eﬀect was observed in the
vehicle control (Suppl. Fig. 2B). In GENCs, we did not observe sig-
niﬁcant eﬀects of S1P on endothelial barrier, consistent with absent
AMPK phosphorylation (Fig. 2F).
S1P induced the phosphorylation of AMPK and enhanced the en-
dothelial barrier in HMEC-1, a cell line shown to express the S1P1 re-
ceptor [39,40]. As S1P had no eﬀect on AMPK and endothelial barrier
in GENCs this raised the question whether the cell line expresses the
S1P1 receptor. To address this question, we performed ﬂow cytometry
analysis to examine surface expression of S1P1 in GENCs (Suppl. Ma-
terial). The receptor was expressed in this cell line (Suppl. Fig. 3). A
possible explanation for the diﬀerences in HMEC-1 and GENCs might be
diﬀerential expression of S1P2, a receptor partially antagonizing the
eﬀects of S1P1 [41]. The balance between the two receptors inﬂuences
S1P action on endothelial permeability [41]. It was shown in vivo that
S1P was unable to prevent barrier breakdown in rat cremaster muscle
vasculature unless S1P2-signalling was inhibited by a selective inhibitor
[42]. Taken together, since S1P in the used dosage did not induce
phosphorylation of AMPK in GENCs and did not alter barrier function
despite the presence of S1P1, we hypothesize that this pathway is less
relevant for barrier enhancement in the glomerular endothelium of
mice. However, further studies should address the role of the diﬀerent
S1P receptors in the S1P-AMPK-interrelationship.
3.3. AMPK partially mediates the barrier-stabilizing eﬀects of S1P in
HMEC-1
Barrier protection mediated by either S1P [6–8] or AMPK activation
[22–24] was reported in a variety of endothelial cell lines and we were
able to demonstrate AMPK phosphorylation as well as an increase in
endothelial barrier function upon S1P stimulation in HMEC-1. There-
fore, the question arises whether S1P-mediated AMPK phosphorylation
also contributes to the stabilization of endothelial barriers. To further
examine this hypothesis, we established a reverse transfection protocol
to knock down AMPK α1/2 in HMEC-1. AMPK was knocked down
partially with 44% ± 11% of AMPK α1/2 remaining as determined by
immunoblot analysis (Fig. 3A). When using Stain-Free™ in comparison
to β-actin loading control for quantiﬁcation, the knockdown eﬃciency
was similar with 43% ± 9% of AMPK α1/2 remaining (Suppl. Fig. 4).
Of note, cells with AMPK knockdown did not exhibit a diﬀerent phe-
notype compared to cells treated with scrambled siRNA before cells
were stimulated with S1P. In AMPK-deﬁcient cells, stimulation with
1 μM S1P induced a rapid short-term decrease in resistance followed by
an increase that was slightly lower than in cells treated with scrambled
siRNA (Fig. 3B). Overall, the proﬁle of endothelial resistance was si-
milar. However, mean changes in resistance were signiﬁcantly lower in
AMPK-deﬁcient cells compared with cells treated with scrambled siRNA
(p= 0.0059, Fig. 3C).
Our observation that the endothelial barrier is not compromised in
AMPK-deﬁcient microvascular endothelial cells under basal conditions
is in line with the study by Creighton et al. demonstrating that AMPK
contributes to the development of endothelial barriers but not to their
maintenance [43]. This as well as the achieved proportion of the AMPK
knockdown of 44 ± 11% remaining AMPK α1/2 might explain the
relatively small eﬀect of S1P stimulation after AMPK knockdown ob-
served in our study. Although the eﬀect is small, the change in re-
sistance in response to S1P was observed reproducibly in every re-
plicate experiment performed indicating that AMPK could be involved
in the regulation of S1P-mediated barrier stabilization. Furthermore,
the relatively small eﬀect in our experiments might be attributed to the
Fig. 2. S1P induces AMPK phosphorylation at Thr172 and increases barrier function in HMEC-1 but not in GENC. (A) Representative Western blots of HMEC-1 and
(B) corresponding semi-quantiﬁcation data expressed as mean+SD of 4 experiments. *p < 0.05 vs. unstimulated (Mann-Whitney-U test). (C) ECIS measurement of
HMEC-1 (n= 9 measurements in 3 independent experiments) stimulated with 1 μM S1P 72 h after cells were seeded (t= 0). Data are expressed as mean ± SD.
*p < 0.05 vs. HMEC-1 at each respective time point indicated by bars (two-way ANOVA with Holm-Sidak post hoc). (D) Representative Western blots of GENC and
(E) corresponding semi-quantiﬁcation data expressed as mean+ SD of 4 experiments. *p < 0.05 vs. unstimulated (Mann-Whitney-U test). (F) ECIS measurement of
GENC (n= 3) stimulated with 1 μM S1P 72 h after cells were seeded (t= 0). Data are expressed as mean ± SD (two-way ANOVA with Holm-Sidak post hoc).
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experimental setup, in which the electrodes of the ECIS™ array are
covered by only approximately 500 cells. Thus, the percentage of AMPK
knockdown might vary between the single experiments. Levine et al.
demonstrated that AMPK phosphorylation by S1P modulates Rac1
signalling, indicating direct eﬀects of S1P-phosphorylated AMPK on the
cytoskeleton [25]. Tight junction molecules are known to regulate en-
dothelial permeability and S1P was shown to contribute to the forma-
tion of tight junctions via Akt- and Rac-signalling [44]. Another well-
known mediator of endothelial permeability, endothelial nitric oxide
synthase (eNOS) [45], was shown to be regulated by S1P [46] and
AMPK [47] resembling a potential link between the two, especially
since S1P-mediated phosphorylation of eNOS was demonstrated to
depend on AMPK in bovine and murine aortic endothelial cells [25,26].
3.4. FTY720 does not prevent endothelial barrier breakdown in our setting
As the S1P-AMPK interrelation appears to play a barrier-enhancing
role in HMEC-1 under basal conditions, we further assessed potential
barrier-protective eﬀects by activating the S1P signalling pathway
under inﬂammatory conditions. S1P has a very short half-life, hence we
tested FTY720 instead. As Dudek et al. reported that FTY720 enhances
barrier function in pulmonary endothelial cells by an alternative
pathway to S1P and the S1P1 receptor [14], we also tested FTY720 in
GENCs. Resistance of HMEC-1 and GENC layers was monitored 24 h
after administration of LPS+Cyt and application of FTY720 or vehicle
(Fig. 4).
In our experimental setup, we observed no signiﬁcant changes in
resistance in HMEC-1, compared with the vehicle control (Fig. 4A). In
GENCs, no eﬀects of FTY720 were observed compared with the vehicle
control (Fig. 4B).
We observed neither positive nor negative eﬀects of FTY720 on the
disturbed endothelial barrier in HMEC-1 or GENCs under the chosen
experimental conditions. While others have described an adverse eﬀect
of the S1P-analogue leading to increased permeability [48], this in-
dicates that FTY720 in the used dosage does not aﬀect the endothelial
barrier negatively during inﬂammation. Contrariwise, in vivo studies
have shown that FTY720 reduced ﬂuid extravasation in a rat model of
sepsis [19] and diminished lung microvascular permeability in LPS-
treated mice [20]. While FTY720 might have protective potential
against inﬂammatory barrier disruption in the kidney, as demonstrated
in a rat model of chronic kidney dysfunction [49], our ﬁndings in
GENCs are in line with our previous observation that FTY720 did not
signiﬁcantly improve kidney function in septic mice [11]. Additionally,
organ speciﬁcity of FTY720-mediated barrier protection may account
for our results: endothelial cells derived from brain microcapillaries
showed protective eﬀects of FTY720 against inﬂammatory barrier
breakdown [15] and we observed beneﬁcial eﬀects of FTY720 on the
cardiac function of septic mice while kidney function was not improved
[11]. Organ speciﬁcity could be mediated by diﬀerential expression of
sphingosine kinases needed for FTY720 activation [50] or varying ex-
pression patterns of S1P receptor subtypes between tissues [51]. Fur-
thermore, the timing of FTY720 administration and the dosage as well
as the degree of the pro-inﬂammatory challenge may inﬂuence poten-
tial eﬀects. This needs to be further investigated.
3.5. Conclusion
We established a reproducible and transferable in vitro model of
inﬂammatory barrier breakdown that allows testing of interventional
strategies. Our model revealed that the response of the endothelium to
inﬂammatory stimuli highly depends on the origin of the endothelial
cells. We furthermore demonstrated AMPK phosphorylation by S1P in
cells of the microvascular but not in the glomerular endothelium and,
for the ﬁrst time, provided evidence for the functional role of the S1P/
Fig. 3. AMPK partially mediates barrier-enhancing eﬀects of S1P in HMEC-1. (A) Representative Western blots of AMPK α1/2 and β-actin loading control and
quantiﬁcation data (mean+ SD, n= 3). (B) ECIS measurement of HMEC-1 reversely transfected with either scrambled siRNA or siRNA against AMPK α1/2 and
stimulated with 1 μM S1P. Data are expressed as mean ± SD of 8–9 single measurements in 3 independent experiments. (C) S1P-induced changes in normalized
mean resistance (relative to 10min before S1P stimulation) of AMPK-deﬁcient HMEC-1 compared to HMEC-1 treated with scrambled siRNA. Data are expressed as
mean+ SD, *p < 0.05 (Mann-Whitney-U test).
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AMPK axis for barrier stabilization. Therefore, cell-type speciﬁc dif-
ferences in the S1P-AMPK axis should be taken into account when
testing interventional strategies to prevent barrier breakdown under
inﬂammatory conditions.
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